Wegovy long term use: what happens after the first year?

Six months in, and the question that comes up every time

Picture this: you've been on Wegovy for half a year. The nausea that troubled you in the first few weeks has mostly faded. The scale has moved noticeably. And now your prescriber is asking what you'd like to do next. For many people this is the first moment they really sit with the question of long term Wegovy use, not as an abstract concept, but as a practical one that affects their next prescription.

The STEP 1 trial, which enrolled over 1,900 adults and ran for 68 weeks, found an average body-weight reduction of around 15% with semaglutide 2.4 mg alongside lifestyle changes, compared with roughly 2.4% with placebo. That is the headline figure. Less quoted is what happened in the STEP 4 extension: participants who continued semaglutide maintained that loss and lost a little more, while those switched to placebo regained the majority of their weight within 12 months. The implication for long term use is hard to sidestep, the medicine appears to work in part by actively maintaining a new physiological equilibrium, not just by triggering a one-off change.

Wegovy's licensed indication covers weight management alongside a reduced-calorie diet and physical activity, and it holds a UK marketing authorisation for adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition. The licence itself does not specify a duration limit. That two-year figure comes specifically from NICE's NHS appraisal, which recommends semaglutide only within specialist weight management services for a maximum of two years, a commissioning boundary, not a clinical ceiling. Private prescribing decisions are made on the patient's individual circumstances at each clinical review.

What changes (and what doesn't) the longer you take it

The side-effect profile of semaglutide in longer-term use broadly mirrors what the early months look like, only quieter. Gastrointestinal effects (nausea, loose stools, reflux, constipation) are most common during dose escalation. On a stable maintenance dose, most people find they become background noise rather than a daily reality. The long term effects of Wegovy that clinical programmes have examined include gallbladder disease (gallstones are seen at modestly higher rates than with placebo), heart rate changes, and the question of thyroid C-cell effects, which has been a regulatory focus since the class was first approved.

In January 2026, the MHRA issued a Drug Safety Update reminding prescribers and patients that acute pancreatitis (though infrequent) is a recognised risk with GLP-1 medicines. Severe stomach pain that spreads to the back, with or without vomiting, warrants urgent medical attention. This applies at any stage of treatment, including during long term use. You can report any suspected side effects at the MHRA's Yellow Card scheme.

What the trials have not shown, over periods of up to four years, is a pattern of new serious harms emerging the longer treatment continues. That is genuinely useful information. It does not mean long term Wegovy use is risk-free or appropriate for everyone, only that the evidence does not reveal a hidden deterioration with time. A GPhC-registered prescriber will weigh your individual health picture at every review, not just at the start.

The stopping problem, and why it matters for how you plan

Perhaps the most clinically significant thing about long term Wegovy use is what happens when treatment ends. The STEP 4 data are clear: weight regain begins relatively quickly after stopping, and within a year most of the loss is reversed. This is not a personal failing. Obesity is a chronic condition shaped by hormonal and neurological signals that GLP-1 medicines actively modulate. When the medicine stops, those signals resume.

That reality has practical consequences. It means the decision to start Wegovy is, for most people, a decision about an ongoing intervention rather than a course with a finish line. It also means that if you are considering cost (and it is reasonable to) the long term picture matters. Our guide to Wegovy costs in the UK explains what the price landscape actually looks like; what it does not change is the clinical picture around duration.

It's worth thinking about continuity of supply too. If you're planning to start treatment ahead of a period that makes consistency tricky (a long holiday, a run of busy Mondays, a month where cash flow is tighter) raising that with your prescriber early makes the plan more realistic. A treatment that's interrupted repeatedly is harder to evaluate and harder to benefit from. For anyone asking whether Wegovy works long term, the honest answer is: yes, for as long as it is taken consistently, under appropriate supervision. The NHS medicines page for semaglutide is a reliable first reference for the plain-language clinical detail, alongside your prescriber.

What ongoing clinical oversight actually involves

Long term semaglutide use is not a set-and-forget situation. That applies whether you are on the NHS or with a private service. Staying on Wegovy long term requires a prescriber to periodically assess whether the treatment is still appropriate: is weight loss being maintained; have any new contraindications emerged; are side effects tolerable; is there a reason to consider a different approach? At nume, every repeat order is reviewed by a real prescriber before it is approved, not processed automatically.

NICE's guidance under TA875 also includes a stopping criterion: if less than 5% weight loss has been achieved after six months on the maintenance dose, continuing is unlikely to be clinically justified. That threshold is not a punishment; it is a signal that the medicine may not be the right tool for that particular person at that particular time, and that a different approach might serve them better.

For a considered view on whether long term Wegovy use is the right path for your circumstances, the place to start is a clinical conversation. Speak to our prescribers, consultations at nume are free, reviewed the same day by a qualified Independent Prescriber, and come with no obligation to proceed.